SCHEMBL13101710

SCHEMBL13101710

CCc1nc2cc(OC(F)(F)F)ccc2c(=O)n1NC(=O)Cc1ccc(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
LMNA P02545 3/20 0.41
CYP3A4 P08684 1/20 0.41
CSNK1D P48730 3/20 0.40
HTT P42858 2/20 0.39
GPR139 Q6DWJ6 3/20 0.38
P2RX7 Q99572 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
WNT3A P56704 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102262 0.94 CYP3A4 (0.42) ALDH1A1LMNACYP3A4CSNK1DHTT
SCHEMBL13101694 0.91 ALDH1A1 (0.44) ALDH1A1LMNACYP3A4CSNK1DHTT
SCHEMBL13101727 0.89 CSNK1D (0.41) ALDH1A1LMNACYP3A4CSNK1DHTT
SCHEMBL13101676 0.89 ALDH1A1 (0.42) ALDH1A1LMNACSNK1DHTTGPR139
SCHEMBL3067313 0.88 ALDH1A1 (0.52) ALDH1A1LMNACYP3A4CSNK1DHTT
SCHEMBL13102276 0.87 TRPV4 (0.44) ALDH1A1LMNACYP3A4CSNK1DHTT
SCHEMBL13102008 0.86 ALDH1A1 (0.39) ALDH1A1LMNACSNK1DHTTMEN1
SCHEMBL13102103 0.86 HDAC1 (0.42) ALDH1A1LMNAHTTMEN1KMT2A
SCHEMBL13102318 0.85 SLC2A1 (0.45) ALDH1A1LMNACSNK1DHTTGPR139
SCHEMBL13101997 0.85 HDAC1 (0.45) ALDH1A1LMNACYP3A4HTTGPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 ALDH1A1 2354/4885LMNA 1121/4885CYP3A4 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.